MX2022013897A - Dominio kelch que contiene variantes de 7b (klhdc7b) y usos de estas. - Google Patents

Dominio kelch que contiene variantes de 7b (klhdc7b) y usos de estas.

Info

Publication number
MX2022013897A
MX2022013897A MX2022013897A MX2022013897A MX2022013897A MX 2022013897 A MX2022013897 A MX 2022013897A MX 2022013897 A MX2022013897 A MX 2022013897A MX 2022013897 A MX2022013897 A MX 2022013897A MX 2022013897 A MX2022013897 A MX 2022013897A
Authority
MX
Mexico
Prior art keywords
klhdc7b
kelch domain
domain containing
methods
containing variants
Prior art date
Application number
MX2022013897A
Other languages
English (en)
Inventor
Aris Baras
Samuelson Meghan Drummond
Kavita Praveen
Lauren Gurski
Goncalo Abecasis
Giovanni Coppola
Manuel Allen Revez Ferreira
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022013897A publication Critical patent/MX2022013897A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6818—Sequencing of polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona métodos para tratar sujetos que tienen pérdida auditiva, métodos para identificar sujetos que tienen un mayor riesgo de desarrollar pérdida auditiva y métodos para detectar moléculas de ácido nucleico de dominio Kelch que contiene variantes 7B (KLHDC7B) y polipéptidos variantes.
MX2022013897A 2020-05-06 2021-05-04 Dominio kelch que contiene variantes de 7b (klhdc7b) y usos de estas. MX2022013897A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063020746P 2020-05-06 2020-05-06
US202063087245P 2020-10-04 2020-10-04
PCT/US2021/030669 WO2021226097A1 (en) 2020-05-06 2021-05-04 Kelch domain containing 7b (klhdc7b) variants and uses thereof

Publications (1)

Publication Number Publication Date
MX2022013897A true MX2022013897A (es) 2023-02-09

Family

ID=76076529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013897A MX2022013897A (es) 2020-05-06 2021-05-04 Dominio kelch que contiene variantes de 7b (klhdc7b) y usos de estas.

Country Status (7)

Country Link
US (3) US11674177B2 (es)
EP (1) EP4146825A1 (es)
JP (1) JP2023524824A (es)
CN (1) CN115667548A (es)
CA (1) CA3181178A1 (es)
MX (1) MX2022013897A (es)
WO (1) WO2021226097A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115362269A (zh) * 2020-03-06 2022-11-18 雷杰纳荣制药公司 Fascin-2(FSCN2)变体及其用途
MX2022013897A (es) * 2020-05-06 2023-02-09 Regeneron Pharma Dominio kelch que contiene variantes de 7b (klhdc7b) y usos de estas.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187817B1 (en) * 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
ES2497716T3 (es) * 2002-01-04 2014-09-23 Sound Pharmaceuticals Incorporated Composiciones para utilizar en métodos destinados a tratar la pérdida auditiva
WO2017161387A1 (en) * 2016-03-18 2017-09-21 Reid Christopher Brian Compositions of natural extracts and use thereof in methods for preventing or treating diseases
WO2016054096A1 (en) * 2014-09-30 2016-04-07 Illumina, Inc. Modified polymerases for improved incorporation of nucleotide analogues
US9758781B2 (en) 2014-09-30 2017-09-12 University Of Iowa Research Foundation Methods to prevent and treat autosomal dominant non-syndromic hearing loss
US20170226570A1 (en) * 2014-10-17 2017-08-10 The Hospital For Sick Children Dna methylation markers for overgrowth syndromes
US20170306406A1 (en) * 2014-10-22 2017-10-26 The Hospital For Sick Children Dna methylation markers for neurodevelopmental syndromes
EP3474852A1 (en) * 2016-06-23 2019-05-01 The Charles Stark Draper Laboratory, Inc. Method and process for quantitative evaluation of pharmacokinetics, therapeutic effects and safety of delivery of drug compounds to the inner ear for treatment of auditory diseases
MX2022013897A (es) * 2020-05-06 2023-02-09 Regeneron Pharma Dominio kelch que contiene variantes de 7b (klhdc7b) y usos de estas.

Also Published As

Publication number Publication date
US20210348228A1 (en) 2021-11-11
EP4146825A1 (en) 2023-03-15
US11674177B2 (en) 2023-06-13
JP2023524824A (ja) 2023-06-13
US20230366024A1 (en) 2023-11-16
CA3181178A1 (en) 2021-11-11
US20250250631A1 (en) 2025-08-07
WO2021226097A1 (en) 2021-11-11
US12258627B2 (en) 2025-03-25
CN115667548A (zh) 2023-01-31

Similar Documents

Publication Publication Date Title
CL2020000343A1 (es) Métodos y materiales para evaluar y tratar el cáncer.
MX2023007012A (es) Metodos para tratar los trastornos metabolicos y las enfermedades cardiovasculares con inhibidores de la subunidad beta e de la inhibina (inhbe).
BR112014026648A2 (pt) determinação de uma porção futura de um programa de mídia atualmente apresentado
Pereira et al. Sickle cell disease: quality of life in patients with hemoglobin SS and SC disorders
Fontenot et al. Gender, race, and electrophysiologic characteristics of the branched recurrent laryngeal nerve
BR112019006710A2 (pt) métodos aprimorados para avaliação do estado da uch-l1 em amostras de pacientes
MX2022013897A (es) Dominio kelch que contiene variantes de 7b (klhdc7b) y usos de estas.
WO2015157407A8 (en) Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
BR112016007630A2 (pt) análise e rastreamento de resultado clínico
Vidal‐Ribas et al. Deficits in emotion recognition are associated with depressive symptoms in youth with disruptive mood dysregulation disorder
BRPI0720035A2 (pt) métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
BR112022020884A2 (pt) Processos de enriquecimento de vesículas extracelulares (evs) específicas e de processo de identificação de vesículas extracelulares, processo para determinar um tratamento para um paciente com câncer e kit
CL2017002420A1 (es) Detección de lesión cerebral
BR112018014762A2 (pt) método de tratamento da doença de alzheimer (da) precoce
BR112022006013A2 (pt) Dispositivo e método para a determinação não inva-siva de analito
MX2021009983A (es) Variantes del componente 1 de canales ionicos mecanosensibles de tipo piezo (piezo1) y usos de estas.
BR112014015424A2 (pt) detecção de células derivadas de tecido do cordão umbilical humano
MX2021007938A (es) Tratamiento de trastornos respiratorios con inhibidores de la araquidonato 15-lipooxigenasa (alox15).
MX2023014341A (es) Tratamiento de la enfermedad cerebrovascular con agentes de la proteina 3 homologa de notch del locus neurogenico (notch3).
NZ780568A (en) Treatment of hyperglycemia with solute carrier family 39 member 5 (slc39a5) inhibitors
Stujenske et al. Prelimbic-dependent activation of amygdala somatostatin interneurons signals non-aversive cues to promote discrimination
Fistikci et al. Sociotropic personality traits positively correlate with the severity of social anxiety
Mudla N-acetylcysteine: A Possible Treatment for Hairpulling in Trichotillomania
Gázquez Linares et al. Mediating role of anxiety and emotional intelligence in predicting to academic burnout in adolescents